Lergotrile (, ; developmental code name LY-79907) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity.
The drug's hydroxylated metabolite 13-hydroxylergotrile is 100-fold more potent as a dopamine receptor agonist than lergotrile itself in vitro.